Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


Get your full text copy in PDF

Extraovarian Primary Peritoneal Carcinomatosis: A Case Report

Gregory Nicolas, Tony Kfoury, Hassan Fawaz, Mahdi Issa

(Medical Student, LAUMRCH, Beirut, Lebanon)

Am J Case Rep 2017; 18:714-718

DOI: 10.12659/AJCR.902801

BACKGROUND: Extraovarian primary peritoneal carcinoma (EOPPC) is a rare malignant epithelial tumor with an age-adjusted incidence rate of 6.78 per million, which arises from the peritoneal lining with minimal or no ovarian involvement. EOPPC is a diagnosis of exclusion with the absence of other identifiable primary sites and after surgical assessment and consideration of the histological report to evaluate the extent of ovarian invasion.
CASE REPORT: A 66-year-old woman complained of mild postprandial epigastric pain. Physical exam revealed positive bowel sounds over all 4 quadrants, with a soft, non-tender abdomen. Distension and dullness to percussion were noted. A CT scan revealed peritoneal fluid, and evaluation of the peritoneal fluid showed an elevated white blood cell count, while fulfilling criteria for exudate. There was no bacterial growth from the peritoneal fluid. Serum tumor markers CEA were significantly elevated, suggestive of an underlying malignancy. An exploratory laparoscopy confirmed diffuse carcinomatosis in the omentum, the coloparietal region bilaterally, as well as surrounding small bowel loops, the transverse and sigmoid colon, and the rectum. A bilateral oophorectomy was performed and 2 biopsies from the thickened peritoneum were taken. The histomorphological features from the pathology examination concluded the patient had peritoneal serous carcinoma with uninvolved ovaries.
CONCLUSIONS: EOPPC may be misdiagnosed as epithelial ovarian cancer, and should be considered in patients with peritoneal carcinomatosis, normal-sized ovaries, and no identifiable primary lesion. Since the common therapeutic strategies achieve comparable survival rates, failed recognition may be without consequences. However, to further improve survival, optimal cytoreductive surgery is essential and should be made a priority in disease management.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree